Cargando…
Learning from past failures: Challenges with monoclonal antibody therapies for COVID-19
COVID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic interventions. Due to their safety, specificity, and potential for rapid advancement into the clinic, monoclonal antibodies (mAbs) represent a highly promising class of antiviral or anti-inflammator...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier B.V.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836766/ https://www.ncbi.nlm.nih.gov/pubmed/33276017 http://dx.doi.org/10.1016/j.jconrel.2020.11.057 |